Article Text

PDF
Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs
  1. J. L. Tomlin, BSc, BVetMed, MRCVS1,
  2. C. Sturgeon, BVetMed, MRCVS1,
  3. M. J. Pead, BVetMed, PhD, MRCVS1 and
  4. P. Muir, BVSc, MVetClinStud, PhD, MACVSc, MRCVS, DipACVS, DipECVS1,1
  1. 1 The Royal Veterinary College, Department of Small Animal Medicine and Surgery, Hawkshead Lane, North Mymms, AL9 7TA

Abstract

The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla. A spiral fracture associated with the tibial tumour healed after it was stabilised with an external skeletal fixator. Both dogs remained comfortable and survived for 12 and 10 months respectively after diagnosis, despite the fact that neither primary tumour was resected.

    Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.